Drug Guidance for Subsidy 10/02/2025 Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia The Ministry of Health’s Drug Advisory Committee has recommended: Recombinant varicella zoste... See all × 10/02/2025 Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia The Ministry of Health’s Drug Advisory Committee has recommended: Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in: adults 60 years of age or older; and adults 18 years of age or older at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy. Funding status RRecombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection is recommended for inclusion on the MOH Subsidised Vaccine List (SVL) for the abovementioned indication from September 2025. RThe recombinant varicella zoster virus glycoprotein E injection should be used in line with the additional clinical criteria listed in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Shingrix Injection, Powder, Lyophilized, For Liposomal Suspension 50 mcg/0.5 mL Alexandra Hospital Changi General Hospital KK Women's and Children's Hospital Khoo Teck Puat Hospital National Cancer Centre National Skin Centre Ng Teng Fong General Hospital National University Hospital National University Polyclinics Sengkang General Hospital Singapore General Hospital Woodlands Health Campus
INTRAMUSCULAR Select a brand starting with the letter: S SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML [SIN16079P]